Bio-ink

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Retrieved on: 
Wednesday, January 4, 2023
Allergan, 3D bioprinting, Patient, Tissue, Food, Intellectual property, Anatomy, Regeneration, Genetic engineering, COVID-19, Marketing, Safety, Clinical trial, Bio-ink, Breast, Public expenditure, Regenerative medicine, Perception, Annual report, AbbVie, Risk, 3D, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medical device, Medical imaging

The objectives of the study were fully achieved, including the evaluation of the safety and efficacy of the bioprinted breast implants.

Key Points: 
  • The objectives of the study were fully achieved, including the evaluation of the safety and efficacy of the bioprinted breast implants.
  • "Our regenerative breast implants have the potential to address the safety challenges associated with silicone implants while providing a more natural looking and feeling aesthetic result.
  • CollPlant's bioprinted regenerative implants aim to overcome the challenges of existing breast procedures using silicone implants or autologous fat transfer.
  • CollPlant's regenerative breast implants are comprised of the Company's proprietary plant-derived rhCollagen, an ideal building block for regenerative medicine implants attributed to better bio-functionality, superior homogeneity, and improved safety.

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

Retrieved on: 
Tuesday, January 3, 2023
Allergan, TAL, 3D bioprinting, Gel, Tissue, Drug discovery, Intellectual property, Regeneration, Genetic engineering, COVID-19, Marketing, Safety, Clinical trial, Bio-ink, Public expenditure, Perception, CLGN, Annual report, AbbVie, Risk, 3D, Pharmaceutical industry, 3D printing

Collink.3D™ 50L adds to CollPlant's growing portfolio of commercial bioinks launched over the last year, Collink.3DTM 50 and Collink.3DTM 90.

Key Points: 
  • Collink.3D™ 50L adds to CollPlant's growing portfolio of commercial bioinks launched over the last year, Collink.3DTM 50 and Collink.3DTM 90.
  • "Much like our other bioinks, Collink.3DTM 50L provides a state-of-the-art animal-free alternative to existing commercial bioinks, enabling high-resolution, scalable and reproduceable bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology.

3D Bioprinting Global Market Report 2022: Advancements in Technology, Increasing R&D Expenditure, and Rising Disposable Income to Fuel Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Health Technology, 3D, Conditional sentence, Growth, Region, Magnetic levitation, Medicine, Bio-ink, USD, Food, 3D printing, Renewable energy

The global 3D bioprinting market size is estimated to be USD 1,745.2 million in 2021 and is expected to witness a CAGR of 21.75% during the forecast period.

Key Points: 
  • The global 3D bioprinting market size is estimated to be USD 1,745.2 million in 2021 and is expected to witness a CAGR of 21.75% during the forecast period.
  • Rising geriatric population with chronic illness cases is a key driver for the growth of the global 3D bioprinting market.
  • Additionally, the advancements in technology, increasing R&D expenditure, and rising disposable income are some of the other drivers propelling the market growth.
  • Nevertheless, the expensive cost of technology and un-skilled personnel are expected to restrain the global market growth.

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Retrieved on: 
Tuesday, November 15, 2022
Transfer, Perception, Doctor of Philosophy, Intellectual property, Tuba City Regional Health Care Corporation, SEC, Ramot at Tel Aviv University, 3D, Technology, Allergan, MD, Patient, Colitis, Forward-looking statement, Harvard University, Annual report, City, Wyss Institute, Risk, Genetic engineering, Industry, 3D bioprinting, Company, Newsweek, 3D Systems, Ulcerative colitis, Terminology, Tissue, Sheba Medical Center, Research, Marketing, Pediatric gastroenterology, COVID-19, CEO, NASDAQ, Form 20-F, Inflammatory bowel disease, Wyss Institute for Biologically Inspired Engineering, Hospital, Drug discovery, Inflammatory Bowel Diseases, Clinical trial, AbbVie, Bio-ink, Drug development, Disease, Tel HaShomer, Public expenditure, Medical imaging, Pharmaceutical industry, Medical device, Tel Aviv University

Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

Key Points: 
  • Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
  • Kit Parker at the Wyss Institute at Harvard University, Dr. Yael Haberman from the Pediatric Gastroenterology unit of Sheba Medical Center, and CollPlant's team of scientists and engineers.
  • "We are excited to embark on this important collaboration with Tel Aviv University and Sheba Medical Center for what will represent CollPlant's strategic expansion into personalized medicine.
  • About Ramot and Tel Aviv University:
    Ramot is the technology transfer company ofTel Aviv University, one ofIsrael'sforemost research and teaching universities.

CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

Retrieved on: 
Monday, November 7, 2022
Annual report, Company, Bio-ink, 3D, B cell, Perception, Risk, Allergan, Tissue, AbbVie, Intellectual property, 3D bioprinting, Safety, Potency (pharmacology), 2D, Terminology, Form 20-F, COVID-19, Marketing, Printing, Epithelium, Regenerative medicine, Clinical trial, Forward-looking statement, Regeneration, Engineering, Technology, Genetic engineering, Public expenditure, SEC, Drug discovery, Medical imaging, 3D printing

Thus, the most suitable bioink is required for a given application to mimic the physical properties of the target tissue or organ, while ensuring high cell survival.

Key Points: 
  • Thus, the most suitable bioink is required for a given application to mimic the physical properties of the target tissue or organ, while ensuring high cell survival.
  • "We are very excited to continue to broaden our rhCollagen-based bioink offerings, providing our biopharma and academic customers the ability to print a variety of applications," said CollPlant CEO, Yehiel Tal.
  • Collink.3D90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell culture.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.

CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Regeneration, Risk, 3D, Form 20-F, SEC, Clinical trial, Forward-looking statement, 3D bioprinting, COVID-19, Digital health, Marketing, Annual report, Technology, Tissue, Bio-ink, Canaccord Genuity, Company, AbbVie, Financial Services Forum, Diagnosis, Allergan, CLGN, Perception, Westin Hotels & Resorts, Public expenditure, 3D Systems, Terminology, Intellectual property, Pharmaceutical industry

Mr. Rotem's presentation will take place on Thursday, November 17 at 2:00 p.m.

Key Points: 
  • Mr. Rotem's presentation will take place on Thursday, November 17 at 2:00 p.m.
  • Investors attending the event may request a one-on-one meeting with CollPlant through the conference coordinators.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its recombinant human collagen product with CollPlant's proprietary plant-based genetic engineering technology.

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

Retrieved on: 
Monday, October 3, 2022
Terminology, Perception, Company, 3D Systems, 3D bioprinting, SEC, Technology, Risk, Allergan, Clinical trial, Bio-ink, Multimedia, 3D, Form 20-F, Genetic engineering, COVID-19, Dawson, Conference, Regeneration, Collagen, Forward-looking statement, Tissue, Annual report, Intellectual property, Public expenditure, Marketing, AbbVie, Pharmaceutical industry

Mr. Rotem's presentation will take place on Wednesday, October 12th at 14:00-14:25 PM ET.

Key Points: 
  • Mr. Rotem's presentation will take place on Wednesday, October 12th at 14:00-14:25 PM ET.
  • Investors attending the event may request a one-on-one meeting through the conference coordinators.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant based genetic engineering technology.

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

Retrieved on: 
Monday, September 19, 2022
3D Systems, 3D, Bio-ink, Genetic engineering, Company, Regeneration, Technology, 3D bioprinting, Tissue, NASDAQ, Conference, AbbVie, International Conference on Applied Human Factors and Ergonomics, Allergan, Biofabrication, Medical imaging

CollPlant will also have an exhibition booth at the Conference from Sept 25th-28th.

Key Points: 
  • CollPlant will also have an exhibition booth at the Conference from Sept 25th-28th.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology.
  • Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

Retrieved on: 
Tuesday, July 5, 2022
Biofabrication, 3D Systems, TERMIS, Tissue, Genetic engineering, Regenerative medicine, Form 20-F, Ideal, Tissue Engineering and Regenerative Medicine International Society, 3D, COVID-19, Tissue engineering, Marketing, Public expenditure, Company, Industry, Intellectual property, Allergan, AbbVie, 3D bioprinting, Annual report, Terminology, Regeneration, Perception, Exhibition, Clinical trial, Technology, SEC, Risk, NASDAQ, Bio-ink, Forward-looking statement, Medical imaging, Pharmaceutical industry

REHOVOT, Israel, July 5, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), in Toronto, Canada, on July 10-13, 2022.

Key Points: 
  • "We look forward to participating at the TERMIS conference, a leading organization in the field of tissue engineering and regenerative medicine," said Yehiel Tal, CollPlant's Chief Executive Officer.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology.
  • For more information about CollPlant, visit http://www.collplant.com
    This press release may include forward-looking statements.

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

Retrieved on: 
Wednesday, June 29, 2022
Patient, 3D Systems, Tissue, Genetic engineering, Behavior, Form 20-F, 3D, COVID-19, Anatomy, Marketing, Public expenditure, Company, Intellectual property, Allergan, AbbVie, 3D bioprinting, Annual report, Forward-looking statement, Terminology, Regeneration, Food, Perception, Regenerative medicine, Clinical trial, Technology, Breast, SEC, Risk, Animal, Time, Safety, Bio-ink, Regulation of tobacco by the U.S. Food and Drug Administration, Adipose tissue, Medical imaging

"This study is a quantum leap in the development of 3D bioprinted regenerative breast implants," said Yehiel Tal, CollPlant's Chief Executive Officer.

Key Points: 
  • "This study is a quantum leap in the development of 3D bioprinted regenerative breast implants," said Yehiel Tal, CollPlant's Chief Executive Officer.
  • CollPlant's bioprinted regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer.
  • CollPlant's regenerative breast implants are comprised of the Company's proprietary plant-derived rhCollagen, an ideal building block for regenerative medicine implants attributed to better bio-functionality, superior homogeneity, and improved safety.
  • To date, CollPlant has successfullyproduced prototypes of 3D bioprinted implants designed to regenerate breast tissue and evaluated these in a series of preclinical studies.